ATE539089T1 - Cyclische rezeptor-assoziierte-proteine (rap)- peptide - Google Patents

Cyclische rezeptor-assoziierte-proteine (rap)- peptide

Info

Publication number
ATE539089T1
ATE539089T1 AT08732675T AT08732675T ATE539089T1 AT E539089 T1 ATE539089 T1 AT E539089T1 AT 08732675 T AT08732675 T AT 08732675T AT 08732675 T AT08732675 T AT 08732675T AT E539089 T1 ATE539089 T1 AT E539089T1
Authority
AT
Austria
Prior art keywords
rap
receptor
peptides
associated proteins
cyclic
Prior art date
Application number
AT08732675T
Other languages
German (de)
English (en)
Inventor
Christopher Starr
Todd Zankel
Original Assignee
Raptor Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raptor Pharmaceutical Inc filed Critical Raptor Pharmaceutical Inc
Application granted granted Critical
Publication of ATE539089T1 publication Critical patent/ATE539089T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/655—Somatostatins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AT08732675T 2007-03-21 2008-03-21 Cyclische rezeptor-assoziierte-proteine (rap)- peptide ATE539089T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91923807P 2007-03-21 2007-03-21
PCT/US2008/057863 WO2008116171A1 (en) 2007-03-21 2008-03-21 Cyclic receptor-associated protein (rap) peptides

Publications (1)

Publication Number Publication Date
ATE539089T1 true ATE539089T1 (de) 2012-01-15

Family

ID=39591450

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08732675T ATE539089T1 (de) 2007-03-21 2008-03-21 Cyclische rezeptor-assoziierte-proteine (rap)- peptide

Country Status (10)

Country Link
US (1) US8440629B2 (OSRAM)
EP (1) EP2132224B1 (OSRAM)
JP (1) JP2010524849A (OSRAM)
KR (2) KR20100015786A (OSRAM)
CN (1) CN101861334A (OSRAM)
AT (1) ATE539089T1 (OSRAM)
BR (1) BRPI0809234A2 (OSRAM)
CA (1) CA2681522A1 (OSRAM)
MX (1) MX2009010148A (OSRAM)
WO (1) WO2008116171A1 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1583562T3 (da) 2003-01-06 2011-09-19 Angiochem Inc Angiopep-1, beslægtede forbindelser og anvendelser deraf
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
AU2009238187B2 (en) 2008-04-18 2014-03-06 Angiochem Inc. Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
WO2010027802A2 (en) * 2008-08-25 2010-03-11 New York University Methods for treating diabetic wounds
CA2740317A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Etoposide and doxorubicin conjugates for drug delivery
CA2740316A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
CA2745524C (en) 2008-12-05 2020-06-09 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
BRPI0922611A2 (pt) 2008-12-17 2018-11-06 Angiochem Inc inibidores de metaloproteína de matriz de membrana tipo 1 e usos dos mesmos
US9636384B2 (en) * 2009-04-06 2017-05-02 Mayo Foundation For Medical Education And Research Methods for making polymeric nanoparticle-polypeptide complex
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
EP2448965A4 (en) 2009-07-02 2015-02-11 Angiochem Inc MULTIMEPEPTID CONJUGATES AND ITS USES
US20110189084A1 (en) 2010-01-28 2011-08-04 Raptor Pharmaceutical Inc. Method for Treating Liver Disorders with Receptor Associated Protein (RAP) Peptide-Fucosidase Inhibitor Conjugates
WO2011160082A2 (en) 2010-06-17 2011-12-22 New York University Therapeutic and cosmetic uses and applications of calreticulin
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
GB201220474D0 (en) * 2012-11-14 2012-12-26 Sagetis Biotech Sl Polypeptides
EP3038657A2 (en) 2013-08-28 2016-07-06 Bioasis Technologies Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
EP3259280A4 (en) * 2015-02-20 2018-07-18 The Regents of The University of California Methods and compositions for treating glaucoma
DK3307326T3 (da) 2015-06-15 2020-10-19 Angiochem Inc Fremgangsmåder til behandling af leptomeningeal karcinomatose
CN109422801B (zh) * 2017-08-31 2022-07-08 复旦大学 多功能靶向多肽rap及其在制备肿瘤靶向递送系统中的用途
JP2021504492A (ja) * 2017-11-29 2021-02-15 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム 癌治療のための組成物および方法
WO2020139866A2 (en) * 2018-12-27 2020-07-02 Bioaffinity Technologies, Inc. Compositions and methods for treating cancer
US12305171B2 (en) 2018-12-27 2025-05-20 Bioaffinity Technologies, Inc. Compositions and methods for treating cancer
US11572394B2 (en) * 2020-02-16 2023-02-07 Pasteur Institute Of Iran Peptides for targeting LRP6-overexpressed cells
EP3954393A1 (en) 2020-08-13 2022-02-16 Bioasis Technologies Inc. Combination therapies for delivery across the blood brain barrier
CN116286380A (zh) * 2021-12-21 2023-06-23 暨南大学 环五肽类化合物及其在α-糖苷酶抑制剂类降糖药物或预防保健品中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
IT1122765B (it) * 1978-11-06 1986-04-23 Srm Hydromekanik Ab Frizione a dischi multipli
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6238908B1 (en) 1995-06-07 2001-05-29 Aastrom Biosciences, Inc. Apparatus and method for maintaining and growth biological cells
DE69733132D1 (de) 1996-01-16 2005-06-02 Ronald J Sokol Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US6426208B1 (en) 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6585971B1 (en) 1999-11-12 2003-07-01 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US6569661B1 (en) 1999-11-12 2003-05-27 Biomarin Pharmaceutical Inc. Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US6596762B2 (en) 2001-05-17 2003-07-22 The Regents Of The University Of Colorado Antioxidant compositions and use for treatment of hepatic steatosis and steatohepatitis
US7485314B2 (en) 2002-05-06 2009-02-03 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Induction of antigen specific immunologic tolerance
AU2004253471B2 (en) 2003-06-20 2010-05-13 Raptor Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US8877714B2 (en) * 2005-06-14 2014-11-04 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof
US8795627B2 (en) * 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates

Also Published As

Publication number Publication date
BRPI0809234A2 (pt) 2014-09-02
WO2008116171A1 (en) 2008-09-25
KR101801454B1 (ko) 2017-11-24
JP2010524849A (ja) 2010-07-22
US8440629B2 (en) 2013-05-14
EP2132224A1 (en) 2009-12-16
US20100210517A1 (en) 2010-08-19
MX2009010148A (es) 2009-12-01
CA2681522A1 (en) 2008-09-25
EP2132224B1 (en) 2011-12-28
KR20100015786A (ko) 2010-02-12
HK1139162A1 (en) 2010-09-10
CN101861334A (zh) 2010-10-13
KR20150104584A (ko) 2015-09-15

Similar Documents

Publication Publication Date Title
ATE539089T1 (de) Cyclische rezeptor-assoziierte-proteine (rap)- peptide
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
WO2007035716A3 (en) Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
CY1117710T1 (el) Κρυσταλλικοι αναστολεις πρωτεασων εποξυ-κετονων πεπτιδιων και η συνθεση των κετο-εποξειδιων αμινοξεων
CY1117162T1 (el) Μεθοδος κατασκευης αντισωματος fc-ετεροδιμερικων μοριων χρησιμοποιωντας αποτελεσματα ηλεκτροστατικης καθοδηγησης
PH12017500866A1 (en) Targeted xten conjugate compositions and methods of making same
WO2006138343A3 (en) Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
MX2010008206A (es) Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf.
GB201009493D0 (en) Modified recombinant factor viii and von willebrand factor and methods of use
EA201100071A1 (ru) Новые композиции и способы
CY1119265T1 (el) Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου
CY1114887T1 (el) Συνθεσεις και μεθοδοι παρασκευης συνθεσης
EA201100546A1 (ru) Полипептиды, вариабельные домены антител и антагонисты
EA201171494A1 (ru) Миметики белка smac
EA200801531A1 (ru) Способы регулирования содержания маннозы в рекомбинантных белках
EA201491644A1 (ru) Фармацевтические композиции
CY1112924T1 (el) Κυτταροδιαπερατοι αναστολεις της jnk-σηματοδοτικης πορειας μεταγωγης
EA201190326A1 (ru) Полипептиды гормона роста и способы их получения и применения
AR080229A1 (es) Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23)
EA201200515A1 (ru) Полипептиды и их применение
CY1113869T1 (el) Λυοφιλιωμενα σκευασματα ανασυνδυασμενου vwf
EA200971129A1 (ru) Циклические пептиды-антагонисты cxcr4
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister